Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy.

Pain medicine (Malden, Mass.) - 1 May 2015

Gupta Anita, Zheng Lu, Ramanujam Vendhan, Gallagher John

Abstract excerpt

OBJECTIVE: To illustrate the potential value of pharmacogenetic testing to identify patients at risk for nonsteroidal anti-inflammatory drug-induced gastropathy. DESIGN: Case report. SETTING: We report a case encountered in an outpatient setting for pain management. PATIENT: We present a case of a patient treated with celecoxib who developed severe nonsteroidal anti-inflammatory drug-induced gastropathy....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Anti-Inflammatory Agents, Non-Steroidal
Share to Cytochrome P-450 CYP2C9

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gastritis

Share to Genetic Predisposition to Disease

Share to Genetic Testing

Share to Polymorphism, Single Nucleotide

Share to Young Adult

Source

Identifiers

PMID: 25585969
DOI: 10.1111/pme.12654

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel Use of Pharmacogenetic Testing in the Identification of CYP2C9 Polymorphisms Related to NSAID-Induced Gastropathy.PMID 25585969Read ↗

Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal Anti-Inflammatory Drugs.Semantic proximity Read ↗

Genetic susceptibility to nonsteroidal anti-inflammatory drug-related gastroduodenal bleeding: role of cytochrome P450 2C9 polymorphisms.Semantic proximity Read ↗

Pharmacogenetics and the Treatment of Functional Gastrointestinal DisordersSemantic proximity Read ↗

An update on the pharmacogenomics of NSAID metabolism and the risk of gastrointestinal bleeding.Semantic proximity Read ↗

Clinical and pharmacogenetic features of patients with upper gastrointestinal lesions at a multidisciplinary hospital: the role of nonsteroidal anti-inflammatory drugs.Semantic proximity Read ↗

Genetically based impairment in CYP2C8- and CYP2C9-dependent NSAID metabolism as a risk factor for gastrointestinal bleeding: is a combination of pharmacogenomics and metabolomics required to improve personalized medicine?Semantic proximity Read ↗

[Clinical pharmacogenomics for CYP2C8 and CYP2C9: general concepts and application to the use of NSAIDs].Semantic proximity Read ↗

Genetic testing for enzymes of drug metabolism: does it have clinical utility for pain medicine at the present time? A structured review.Semantic proximity Read ↗

The value of CYP2D6 and OPRM1 pharmacogenetic testing for opioid therapy.Semantic proximity Read ↗

Pharmacogenetic Testing for Analgesic Adverse Effects: Pediatric Case Series.Semantic proximity Read ↗

Genetic Determinants of Analgesic Responsiveness: A Focus on CYP2D6 and COMT Polymorphisms in Chronic Pain.Semantic proximity Read ↗

An Explorative Study of CYP2D6's Polymorphism in a Sample of Chronic Pain Patients.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.